Health care resource utilization and costs in Medicare Advantage beneficiaries using glucagon-like peptide-1 receptor agonists vs sodium-glucose cotransporter-2 inhibitors
There were no significant differences in health care resource utilization in the overall cohort between patients taking GLP-1 RA vs those taking SGLT2i, and pharmacy and total health care costs were higher in the GLP-1 RA group. In the obesity subgroup, GLP-1 RA initiators had lower medical costs.
Authors
- Suzanne Dixon (ORCID: https://orcid.org/0000-0003-4173-9103)
- I John (ORCID: https://orcid.org/0000-0002-1720-2018)
- Monica M. Diaz (ORCID: https://orcid.org/0000-0001-9663-5948)
- Andy Bowe (ORCID: https://orcid.org/0000-0002-2715-3440)
- Insiya B. Poonawalla (ORCID: https://orcid.org/0000-0003-2051-8803)
- Mary K. Hayes
- Petir Abdal
Institutions
- Humana (United States) (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-06-27
- DOI
- https://doi.org/10.18553/jmcp.2025.31.7.627
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00